IL6 and amyotrophic lateral sclerosis: These studies, in addition to the well-known increased level of IL-6, IL-1β, and TNF-α in patients with ALS, suggest that peripheral immune alterations/inflammation cause increased hepatocytic synthesis and release of APPs that may augment disease burden, rates of disease progression, and survival times of patients with ALS.